- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Olverembatinib Elicits Efficacy in US Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALL
December 13th 2022, 5:35pm
ASH Annual Meeting and Exposition
Olverembatinib elicited encouraging responses and tolerability in US patients with ponatinib-resistant chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and in patients with CML whose tumors have a T315I mutation.
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
December 13th 2022, 3:00pm
ASH Annual Meeting and Exposition
Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Blinatumomab/Consolidation Chemo Combo Improves OS in MRD-Negative B-cell ALL
December 13th 2022, 3:00pm
ASH Annual Meeting and Exposition
Blinatumomab followed by consolidation chemotherapy led to a 58% reduction in the risk of death compared with standard consolidation chemotherapy alone in adult patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
VITAL Post-Hoc Analysis Shows Birtamimab Significantly Improves Time to All-Cause Mortality in Stage IV AL Amyloidosis
December 13th 2022, 2:50pm
ASH Annual Meeting and Exposition
Birtamimab demonstrated a significant survival benefit in patients with Mayo Stage IV amyloid light chain amyloidosis at month 9.
Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL
December 12th 2022, 11:36pm
Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.
Ibrutinib Improves Time to Next Therapy Vs Acalabrutinib in Real-world Analysis of Patients With CLL
December 12th 2022, 10:09pm
ASH Annual Meeting and Exposition
The use of frontline ibrutinib was associated with a longer time to next treatment compared with acalabrutinib in patients with chronic lymphocytic leukemia.
Amid Withdrawal News, Final DREAMM-2 Analysis Confirms Durability of Belantamab Mafotodin Monotherapy in Relapsed/Refractory Multiple Myeloma
December 12th 2022, 9:25pm
ASH Annual Meeting and Exposition
Single-agent belantamab mafodotin continued to produce rapid, deep, and durable responses in patients with relapsed/refractory multiple myeloma.
Zanubrutinib Demonstrates Efficacy and Safety in Acalabrutinib-Intolerant Patients with B-Cell Malignancies
December 12th 2022, 9:24pm
ASH Annual Meeting and Exposition
Updated results from the ongoing phase 2 BGB-3111-215 trial showed that zanubrutinib provided clinically meaningful benefit to a large majority of efficacy-evaluable patients with B-cell malignancies who were intolerant to acalabrutinib.
Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis
December 12th 2022, 9:07pm
ASH Annual Meeting and Exposition
Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.
Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Prolongs PFS, Compared With Historical Control in Relapsed/Refractory Multiple Myeloma
December 12th 2022, 8:55pm
ASH Annual Meeting and Exposition
The combination of belantamab mafodotin, pomalidomide, and dexamethasone elicited encouraging responses and survival benefits in patients with triple class–exposed or refractory multiple myeloma.
Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura
December 12th 2022, 8:32pm
OncLive News Network: On Location at ASH 2022
In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.
Mosunetuzumab Elicits Long-Term Responses in Relapsed/Refractory Follicular Lymphoma
December 12th 2022, 8:32pm
ASH Annual Meeting and Exposition
Mosunetuzumab demonstrated durable responses and a low rate of adverse events linked with treatment discontinuation in patients with relapsed/refractory follicular lymphoma, according to an updated analysis of the pivotal phase 2 GO29781 study.
Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL
December 12th 2022, 7:23pm
ASH Annual Meeting and Exposition
Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.
Low-Dose Lenalidomide Reduces Risk of Transfusion Dependency, Provides Clonal Response and Safety Benefits in MDS
December 12th 2022, 6:55pm
ASH Annual Meeting and Exposition
Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.
Tisagenlecleucel Elicits Sustained Responses in Relapsed/Refractory Follicular Lymphoma
December 12th 2022, 5:25pm
ASH Annual Meeting and Exposition
Tisagenlecleucel produced durable responses in patients with relapsed/refractory follicular lymphoma, including those with high-risk disease characteristics.
Liso-Cel Second-Line Superiority to Standard of Care Confirmed in LBCL
December 12th 2022, 12:29pm
ASH Annual Meeting and Exposition
Second-line treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation for patients with high-risk relapsed/refractory large B-cell lymphoma.
Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma
December 12th 2022, 12:04am
ASH Annual Meeting and Exposition
Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Dr Berdeja on the Safety and Efficacy of BMS-986393 in R/R Multiple Myeloma
December 11th 2022, 11:56pm
ASH Annual Meeting and Exposition
Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.
Real-World Data Consistent With Patient-Reported Outcomes Regarding Axi-Cel Administration in Relapsed/Refractory LBCL
December 11th 2022, 11:37pm
ASH Annual Meeting and Exposition
Patients receiving axicabtagene ciloleucel reported a temporary reduction in quality of life, followed by statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma.